AbbVie Teams With Iambic on AI-Driven Small Molecule Drug Discovery

AbbVie Inc. (ABBV) announced a multi-year collaboration with clinical-stage life sciences and technology company Iambic on Monday, September 21, 2026, to accelerate discovery and development of small molecule therapies targeting immunology. The partnership aims to produce first-in-class and best-in-class drug candidates, combining Iambic's artificial intelligence-driven discovery platform with AbbVie's development capabilities. Financial terms of the agreement were not disclosed. The deal expands AbbVie's push into AI-assisted drug research as large pharmaceutical companies increasingly compete for computational platforms that can shorten early-stage development timelines.